Other studies have shown that MSI colorectal cancer might be specifically sensitive to compounds inhibiting the phosphatidylinositol 3-kinase (PI3K)–AKT–mammalian target of rapamycin (mTOR) pathway (15). This evidence concerns the gene MTOR and colorectal cancer.